<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput xmlns:ns2="local" id="12216"><DrugName>BMS-196085</DrugName><DrugSynonyms><Name><Value>BMS-196085</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BMS-187413</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>BMS-194449</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>BMS-201620</Value><Types><Type>Analogue</Type><Type>Research Code</Type></Types></Name><Name><Value>obesity therapy, BMS</Value></Name><Name><Value>170686-10-9</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>193480-75-0</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>170686-12-1</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="15065">Bristol-Myers Squibb Co</CompanyOriginator><CompaniesSecondary><Company id="15065">Bristol-Myers Squibb Co</Company></CompaniesSecondary><CrossReferences><SourceEntity id="12216" type="Drug"><TargetEntity id="235525" type="siDrug">BMS-196085</TargetEntity></SourceEntity><SourceEntity id="15065" type="Company"><TargetEntity id="4295903619" type="organizationId">Bristol-Myers Squibb Co</TargetEntity></SourceEntity><SourceEntity id="238" type="ciIndication"><TargetEntity id="E66" type="ICD10"></TargetEntity><TargetEntity id="10029883" type="MEDDRA"></TargetEntity><TargetEntity id="D009765" type="MeSH"></TargetEntity><TargetEntity id="-1640888899" type="omicsDisease"></TargetEntity><TargetEntity id="985" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="837" type="ciIndication"><TargetEntity id="E11" type="ICD10"></TargetEntity><TargetEntity id="10067585" type="MEDDRA"></TargetEntity><TargetEntity id="D003924" type="MeSH"></TargetEntity><TargetEntity id="-1888632793" type="omicsDisease"></TargetEntity><TargetEntity id="509" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="399" type="Action"><TargetEntity id="884" type="Mechanism">Glucose Lowering Agents</TargetEntity></SourceEntity><SourceEntity id="42" type="Action"><TargetEntity id="61" type="Mechanism">beta3-Adrenoceptor Agonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00074" type="ciTarget"><TargetEntity id="16144822471553" type="siTarget">Beta-3 adrenergic receptor</TargetEntity><TargetEntity id="1074885228" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="DX">Discontinued</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="238">Obesity</Indication><Indication id="837">Non-insulin dependent diabetes</Indication></IndicationsSecondary><ActionsPrimary><Action id="42">Beta 3 adrenoceptor agonist</Action></ActionsPrimary><ActionsSecondary><Action id="1389">Lipid metabolism modulator</Action><Action id="399">Hypoglycemic agent</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><EphmraCodes><Ephmra><Code>A8</Code><Name>ANTIOBESITY PREPARATIONS, EXCLUDING DIETETICS</Name></Ephmra></EphmraCodes><LastModificationDate>2017-09-04T14:33:45.000Z</LastModificationDate><ChangeDateLast>2007-12-07T14:06:07.000Z</ChangeDateLast><AddedDate>1996-05-01T12:20:50.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;Bristol-Myers Squibb was evaluating a series of beta-3 adrenoceptor agonists, including &lt;ulink linkID="12216" linkType="Drug"&gt;BMS-196085&lt;/ulink&gt; (structure shown), BMS-194449 and BMS-187413, for the potential treatment of obesity and non-insulin dependent diabetes [&lt;ulink linkID="206604" linkType="reference"&gt;206604&lt;/ulink&gt;]. &lt;ulink linkID="12216" linkType="Drug"&gt;BMS-196085&lt;/ulink&gt; had entered into an initial clinical proof of concept study, however, by July 1999 a company spokesperson confirmed that BMS had no beta-3 agonists in development [&lt;ulink linkID="338264" linkType="reference"&gt;338264&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt; &lt;ulink linkID="12216" linkType="Drug"&gt;BMS-196085&lt;/ulink&gt; elevated plasma levels of free fatty acids at doses which did not produce any beta1- or beta2- mediated side effects when administered bolus iv in man. However, two week continuous iv infusion, up to doses resulting in tachycardia, falied to produce statistically significant changes in the metabolic rate [&lt;ulink linkID="428467" linkType="reference"&gt;428467&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt; &lt;ulink linkID="12216" linkType="Drug"&gt;BMS-196085&lt;/ulink&gt; was fully lipolytic in the monkey with an ED50 value of 0.02 mg/kg. Additionally this compound exhibited excellent selectivity over both beta-1 and beta-2 adrenoreceptors and had an oral systemic bioavailability of &amp;lt;5% [&lt;ulink linkID="296000" linkType="reference"&gt;296000&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;BMS-187413 had been shown to be a potent and selective beta-3 adrenoceptor agonist in vitro, with a profile similar to &lt;ulink linkID="5511" linkType="Drug"&gt;BRL-37344&lt;/ulink&gt; (qv) [&lt;ulink linkID="252368" linkType="reference"&gt;252368&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In vivo lipolysis in African green monkeys 30 min after a dose of 0.5 mg/kg BMS-194449 showed a Kcat (beta-3) value of 21 nM; in addition there was heart-rate increase in the above dose and oral availability was &amp;lt;2% due to a high first pass metabolism [&lt;ulink linkID="297320" linkType="reference"&gt;297320&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;In February 1999, Lehman Brothers predicted a drug from BMS's beta-3 program had a 30% probability of reaching market, with an estimated first launch date in 2005. Assuming a successful launch the analysts predicted peak sales would occur in 2013, with sales of $500 million at that time [&lt;ulink linkID="319225" linkType="reference"&gt;319225&lt;/ulink&gt;]. &lt;/para&gt;&lt;para&gt;Beta-3 agonists with a 1,3-benzodioxole moiety are claimed in US-05488064; substituted sulfonic acids are claimed as beta-3 agonists in US-05491134 [&lt;ulink linkID="311983" linkType="reference"&gt;311983&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="338144" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DX" sortOrder="4">Discontinued</DevelopmentStatus><DiscontinuedReason id="4">Not Reported</DiscontinuedReason><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1999-07-01T00:00:00.000Z</StatusDate><Source id="338144" type="CORPORATE"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="837">Non-insulin dependent diabetes</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-05-01T12:20:51.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="15065">Bristol-Myers Squibb Co</Company><Country id="US">US</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="238">Obesity</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v1.ct.soap.analytics.company.service.api.ls.thomsonreuters.com/">1996-05-01T12:20:50.000Z</StatusDate><Source id="206604" type="CORPORATE"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00074"><Name>Beta 3 adrenoceptor</Name><SwissprotNumbers><Swissprot>O02662</Swissprot><Swissprot>O70432</Swissprot><Swissprot>P13945</Swissprot><Swissprot>P25962</Swissprot><Swissprot>P26255</Swissprot><Swissprot>P46626</Swissprot><Swissprot>Q28524</Swissprot><Swissprot>Q60483</Swissprot><Swissprot>Q95252</Swissprot><Swissprot>Q9TST4</Swissprot><Swissprot>Q9XT57</Swissprot><Swissprot>Q9XT58</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Indexing Updated</Reason><Description>Indexing updated</Description></ReasonForUpdate></ReasonsForUpdate><StructureSmiles><Smiles>CS(=O)(=O)Nc1cc(ccc1O)[C@H](CNC(c2ccc(cc2)OC(F)F)c3ccc(cc3)OC(F)F)O</Smiles><Smiles>CS(=O)(=O)Nc1cc(ccc1O)[C@H](CN[C@H](Cc2ccccc2)c3ccc(cc3)OC(F)F)O</Smiles><Smiles>CCOP(=O)(Cc1ccc(cc1)NC(=O)[C@](C)(c2ccc(cc2)OC)NC[C@@H](c3ccc(c(c3)NS(=O)(=O)C)O)O)OCC</Smiles><Smiles>C[C@H](Cc1ccc(cc1)OCS(=O)(=O)O)NC[C@@H](c2cccc(c2)Cl)O</Smiles></StructureSmiles><PatentFamilies><PatentFamily id="2051351" number="EP-00659737" title="Catecholamine surrogates useful as beta 3 agonists"></PatentFamily><PatentFamily id="2412454" number="EP-02620143" title="Adrenergic beta-3-receptor agonists for use in treatment of aging-related diseases"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="9">New use</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Guangdong Provincial People's Hospital" id="1038712"></CompanyLink><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Bristol-Myers Squibb Co" id="15065"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Individual" id="21144"></CompanyLink><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.api.service.company.analytics.soap.ct.v1.DrugRecordOutput>